Baltimore’s court case against drug distributors McKesson and AmerisourceBergen centers on a proposed 15-year, $472 million annual plan to combat the city’s opioid epidemic through medication-assisted treatment and harm reduction measures. Economist William Padula testified on the plan’s costs as the city seeks additional compensation from the companies, which were found liable for fueling the crisis by distributing addictive painkillers. Originally published in The Baltimore Sun.

Susan Sherman is quoted.